Sana Biotechnology, Inc. (SANA) Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Sana Biotechnology, Inc. NASDAQ:SANA Healthcare · Biotechnology
AH Close $2.35 vs close AH Close $2.35 +0.86% vs close
All Press Release SEC Filings News
Press Release ⚠ 5
Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick
Biotech Insider, a third-party publisher, issued a commentary recapping the August 12 research and option agreement between Avaí Bio's Insulinova joint venture and Milan's Ospedale San Raffaele to combine OSR's stem cell-derived beta cells with Austrianova's Cell-in-a-Box encapsulation technology for diabetes.
The piece is explicit that the underlying agreement funds laboratory work only — no clinical trial, IND, regulatory pathway, timeline, or data readout date has been disclosed — and notes Vertex's own encapsulation attempt (VX-264) previously showed more work was needed.
The publisher, Market Equities Limited, discloses it owns AVAI shares, was previously paid for Avaí Bio advertising and digital media services, and reserves the right to trade the stock at any time, so the article should be treated as promotional investor-awareness content rather than issuer disclosure.
• 1mo ago AI analysis › SEC Filing ⚠ 5
SANA: 8-K · other
Sana Biotechnology furnished an updated corporate presentation dated September 8, 2026 under Item 7.01 of Form 8-K, which management intends to discuss at investor conferences. The company frames the next 12 months as potentially transformative for its pipeline.
The presentation highlights first-in-human data for UP421, a hypoimmune islet cell product transplanted into a type 1 diabetes patient at Uppsala University Hospital without immunosuppression, where all primary and secondary endpoints were met and cell survival and function were demonstrated through 14 months.
For its scalable SC451 stem cell-derived islet program, Sana targets filing an IND and starting a Phase 1/2 trial in 2026, supported by a Mayo Clinic collaboration that brings capital and helps build a broad patient delivery model.
On the in vivo CAR T platform, Sana sees potential to share first-in-human data for SG293 in non-Hodgkin lymphoma in the first half of 2027 and to begin a clinical study of SG227 in multiple myeloma as early as 2027.
SEC 8-K • 1mo ago Press Release
Sana Biotechnology to Present at September 2026 Investor Conferences
Sana Biotechnology announced that management will present at four upcoming investor conferences in September 2026.
The scheduled events include the Wells Fargo Healthcare Conference, Citi Biopharma Back-to-School Conference, Morgan Stanley Global Healthcare Conference, and the HC Wainwright Global Investment Conference.
Live webcasts of the presentations will be available on the company's website, with replays accessible for 30 days following each event.
• 1mo ago AI analysis › SEC Filing ● Major ⚠ 7
SANA: 10-Q · periodic report
Sana Biotechnology's Q2 2026 10-Q discloses substantial doubt about the company's ability to continue as a going concern, with management stating current capital resources may not fund planned operations for at least one year. The clinical-stage biotech has no product revenue and an accumulated deficit of $2.0 billion.
The quarterly net loss narrowed to $63.6 million, or $0.22 per share, from $93.8 million a year earlier, helped by portfolio cuts that suspended the SC291 and SC262 allogeneic CAR T programs. Cash, cash equivalents, and marketable securities stood at $160.5 million at June 30, 2026, against first-half operating cash burn of $70.2 million.
Funding has come at a steep dilution cost: Sana sold 21.6 million shares for $68.6 million net under its $150 million TD Cowen ATM facility in Q2, plus $25.0 million from Mayo Clinic at $3.33 per share under a stock purchase and license deal tied to the SC451 diabetes program. Mayo Clinic has not yet elected to buy an additional $25.0 million of shares, with that option expiring August 31, 2026.
Key catalysts ahead include an IND filing and Phase 1/2 start for SC451 in type 1 diabetes and initial clinical data for SG293 in non-Hodgkin lymphoma, both possibly as early as this year. A securities class action over statements about SC291 remains pending in the Western District of Washington, stayed until a joint status report due September 9, 2026.
SEC 10-Q • 2mo ago AI analysis › Press Release
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
Sana Biotechnology reported progress on its lead programs, preparing for Phase 1/2 trials of SC451 for type 1 diabetes and first-in-human data for SG293 in non-Hodgkin lymphoma.
The company highlighted positive durability data for UP421 published in The New England Journal of Medicine and announced a strategic collaboration with Mayo Clinic which included a $25 million equity investment.
Financially, Sana ended Q2 with $160.5 million in cash, bolstered by $93.3 million in net proceeds from ATM sales and the Mayo investment, extending its expected cash runway into mid-2027.
• 2mo ago AI analysis › News
Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $9.50 Consensus PT from Brokerages
defenseworld.net • 2mo ago News
Sana (SANA) Upgraded to Buy: Here's What You Should Know
zacks.com • 3mo ago Press Release ● Major ⚠ 3
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
Sana Biotechnology announced that The New England Journal of Medicine published a peer-reviewed letter highlighting 14-month data for UP421, showing that hypoimmune-modified islet cells survived and produced insulin without immunosuppression.
The study demonstrated safety and durable cell function via C-peptide production, though the low-dose trial was not designed to show improved glycemia.
Based on these findings, Sana plans to file an IND application and initiate a Phase 1/2 trial for its stem cell-derived therapy SC451 as early as this year.
• 3mo ago AI analysis › Press Release
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
Sana Biotechnology announced it will present clinical data from a first-in-human study of UP421, an allogeneic islet cell therapy engineered with its hypoimmune platform, at the EASD Annual Meeting 2026.
The study involves transplanting the therapy into a type 1 diabetes patient without immunosuppression, highlighting the potential for durable immune evasion.
The presentation is scheduled for October 2, 2026, in Milan, Italy.
• 3mo ago AI analysis › News
Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com • 4mo ago SEC Filing
SANA: 8-K · proxy statement
Sana Biotechnology, Inc. reported the final voting results from its 2026 annual meeting of stockholders held on June 4, 2026. Stockholders elected all three Class II director nominees—Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D.—to serve three-year terms expiring in 2029.
The company also disclosed that stockholders ratified the appointment of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification vote was overwhelmingly in favor, with over 203 million votes cast for the proposal against approximately 831,000 votes against.
SEC 8-K • 4mo ago Press Release
Sana Biotechnology to Present at June 2026 Investor Conferences
Sana Biotechnology will present at two major healthcare investor conferences in June 2026.
The company is scheduled to speak at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9.
Webcasts of the presentations will be available on Sana’s Investor Relations website, with replays accessible for 30 days.
• 4mo ago AI analysis › SEC Filing ⚠ 1
SANA: 8-K · offering registration
Sana Biotechnology, Inc. announced the sale of 21,607,878 shares of its common stock pursuant to an amended and restated sales agreement with TD Securities (USA) LLC.
The transaction generated aggregate net proceeds of approximately $69.0 million for the company.
This at-the-market (ATM) offering provides additional liquidity for operations and research but results in dilution to existing shareholders.
SEC 8-K • 5mo ago Press Release ⚠ 2
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
Sana Biotechnology sold 21.6 million shares through its ATM facility, generating net proceeds of approximately $69 million.
Combined with a previously announced $25 million investment from the Mayo Clinic, the company has raised a total of $94 million since the end of the first quarter of 2026.
This capital infusion extends Sana's expected cash runway to mid-2027, supporting its engineered cell therapy development programs.
• 5mo ago AI analysis › SEC Filing
SANA: 8-K · earnings release
Sana Biotechnology, Inc. reported its first quarter 2026 financial results, with a cash position of $101.1 million and a pro forma cash position of $128.9 million, including a $25.0 million equity investment from Mayo Clinic. The company also announced a strategic collaboration with Mayo Clinic to advance the development of SC451, a gene-modified, stem cell-derived pancreatic islet cell therapy for type 1 diabetes.
Sana shared positive clinical results from an investigator-sponsored trial of UP421, an allogeneic primary islet cell therapy, which showed ongoing survival and function of pancreatic beta cells in a patient with type 1 diabetes without the use of immunosuppression. The company is making progress toward starting clinical trials for SC451 and SG293 later this year.
Sana also advanced its preclinical pipeline, particularly SG227, a CD8-targeted fusosome for multiple myeloma, with clinical testing expected to begin as early as mid-2027. The company appointed Brian Piper as its new Chief Financial Officer, bringing extensive financial management experience in the biotechnology sector.
For the three months ended March 31, 2026, Sana reported a net loss of $47.2 million, or $0.17 per share, compared to a net loss of $49.4 million, or $0.21 per share, for the same period in 2025. Research and development expenses decreased by $8.5 million, primarily due to lower personnel-related expenses and the suspension of allogeneic CAR T programs.
SEC 8-K • 5mo ago AI analysis › Press Release
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
Sana Biotechnology announced it will present at the BofA Securities 2026 Healthcare Conference on May 12, 2026.
CEO Steve Harr will deliver a business overview and update, with the session webcast live at 2:20 p.m. PT.
A replay will be available on Sana's investor relations website for 30 days following the event.
• 5mo ago AI analysis › 
